Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 4,201–4,300 of 15,747
Boulton, S., Poutou, J., Martin, N. T., Azad, T., Singaravelu, R., Crupi, M. J. F., Jamieson, T. R., He, X., Marius, R. M., Petryk, J., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.10.008 · Cited by 26
“Antibody titers from our vaccine were also similar to those reported for the mRNA and Adenovirus vector-based vaccines currently in use.(4,5,73,76)”
The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom
Wu, J., Zhang, L., Zhang, Y., Wang, H., Ding, R., Nie, J., Li, Q., Liu, S., Yu, Y., Yang, X., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.687869 · Cited by 23
“The BNT162b2 vaccine from BioNTech/Pfizer and mRNA-1273 produced by Moderna has been shown to be more than 90% effective in preventing COVID19 (3, 16).”
BackgroundAcute kidney injury after COVID-19 vaccines: a real-world study
Luo, H., Li, X., Ren, Q., Zhou, Y., Chen, G., Zhao, B., & Li, X. (2022) · Renal Failure · doi:10.1080/0886022x.2022.2081180 · Cited by 24
Review: N1-methyl-pseudouridine (m1Ψ): Friend or foe of cancer?
Rubio‐Casillas, A., Cowley, D., Raszek, M., Uversky, V. N., & Redwan, E. M. M. M. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.131427 · Cited by 32
Allergic Reactions After the Administration of COVID-19 Vaccines
Bian, S., Li, L., Wang, Z., Cui, L., Xu, Y., Guan, K., & Zhao, B. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.878081 · Cited by 25
Plants as Biofactories for Therapeutic Proteins and Antiviral Compounds to Combat COVID-19
England, C., TrejoMartinez, J., PerezSanchez, P., Karki, U., & Xu, J. (2023) · Life · doi:10.3390/life13030617 · Cited by 27
“So far, COVID-19 vaccines based on messenger RNA (mRNA) (Pfizer/BioNTech, USA/Germany Life 2023, 13, 617 3 of 26 and Moderna, USA) [20], adenovirus vectors (Johnson & Johnson, USA; AstraZeneca, UK and Sputnik V) [21], subunit protein vaccine (Novavax, USA) [22], and inactivated virus (Sinopharm/Sinovac, China) [23] ha…”
BackgroundPeet, C. J., Papadopoulou, C., Sombrito, B. R. M., et al. (2021) · Rheumatology Advances in Practice · doi:10.1093/rap/rkab043 · Cited by 23
Oyebanji, O. A., Wilson, B. M., Keresztesy, D., Carias, L. L., Wilk, D. J., Payne, M., Aung, H., Denis, K. S., Lam, E. C., Rowley, C. F., et al. (2021) · Aging Clinical and Experimental Research · doi:10.1007/s40520-021-01987-9 · Cited by 20
COVID-19 Vaccines in Pakistan: Efficacy, Adverse Effects and Availability
Siddique, S., & Ahmed, S. (2021) · Journal of Islamabad Medical & Dental College · doi:10.35787/jimdc.v10i2.723 · Cited by 33
“clinical trial, while the efficacy of Vaxzevria (formerly known as AstraZeneca) is claimed to be 70% in a study by Voysey and colleagues.(12,13) Another report by Logunov and colleagues affirms 91.”
BackgroundRüthrich, M. M., Giesen, N., Mellinghoff, S. C., Rieger, C. T., & von Lilienfeld‐Toal, M. (2022) · Vaccines · doi:10.3390/vaccines10020182 · Cited by 24
Zhou, P.-P., Song, G., He, W.-T., Beutler, N., Tse, L.-P. V., Martinez, D. R., Schäfer, A., Anzanello, F., Yong, P., Peng, L., et al. (2022) · bioRxiv · doi:10.1101/2022.03.04.479488 · Cited by 13
Piché‐Renaud, P., Morris, S. K., & Top, K. A. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15625 · Cited by 23
“With 21 720 and 15 210 participants having been vaccinated in Phase 3 clinical trials from Pfizer and Moderna, respectively, no cases of myocarditis or pericarditis were initially identified following vaccination.(44,45) In this section of the review, we discuss the systems that identified and characterized the safety…”
BackgroundAbo-Helo, N., Muhammad, E., Ghaben-Amara, S., Panasoff, J., & Cohen, S. (2021) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.07.021 · Cited by 23
Pandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101003 · Cited by 23
Mourtgos, S. M., & Adams, I. T. (2021) · Police Practice and Research · doi:10.1080/15614263.2021.1894937 · Cited by 22
Cao, H., Wang, Y., Luan, N., & Liu, C. (2021) · Vaccines · doi:10.3390/vaccines9040310 · Cited by 23
Li, W.-W., Chen, Y.-Z., Prévost, J., et al. (2021) · bioRxiv · doi:10.1101/2021.08.02.454546 · Cited by 64
“While over ∼1 billion vaccines have been administered as of today (Baden et al., 2020; Folegatti et al., 2020; Logunov et al., 2021; Polack et al., 2020; Sadoff et al., 2021a; Sadoff et al., 2021b; Voysey et al., 2021), the pandemic remains uncontrolled in many countries and new variants, including…”
Novel case of takotsubo cardiomyopathy following COVID-19 vaccination
Stewart, C., Gamble, D. T., & Dawson, D. K. (2022) · BMJ Case Reports · doi:10.1136/bcr-2021-247291 · Cited by 23
Disentangling post-vaccination symptoms from early COVID-19
Canas, L. S., Österdahl, M. F., Deng, J., Hu, C. Y., Selvachandran, S., Polidori, L., May, A., Molteni, E., Murray, B. A. K., Chen, L., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101212 · Cited by 24
“However, although there were some differences in frequencies, most symptoms were reported in both PB and O-AZ pivotal trials [4,5,8,10].”
Sarnelli, G., Re, A., Pesce, M., Lu, J., Esposito, G., Sanseverino, W., Corpetti, C., Franzin, S. B., Seguella, L., Palenca, I., et al. (2023) · Biomolecules · doi:10.3390/biom13030569 · Cited by 24
Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infectionPreprint
Vaca, G. B., Meyer, M., Cadete, A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.11.523616 · Cited by 23
COVID-19 Vaccine–Related Myocardial and Pericardial Inflammation
Furqan, M. M., Chawla, S., Majid, M., Mazumdar, S., Mahalwar, G., Harmon, E., & Klein, A. L. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01801-6 · Cited by 26
“Molecular mimicry between the spike protein of SARSCoV-2 and self-antigens is another potential mechanism that may result in myocarditis following vaccination [6].”
BackgroundSmith, A. P., Williams, E. P., Plunkett, T. R., Selvaraj, M., Lane, L. C., Zalduondo, L., Xue, Y., Vogel, P., Channappanavar, R., Jonsson, C. B., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.894534 · Cited by 30
Adjuvants: friends in vaccine formulations against infectious diseases
Manríquez, G. G. G., & Tuero, I. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1934354 · Cited by 25
Sharma, P., Mishra, S., Basu, S., et al. (2021) · medRxiv · doi:10.1101/2021.06.07.21258447 · Cited by 21
“However, the real-world effectiveness of vaccines may differ from the efficacy reported in clinical trials due to a multitude of factors including the dynamics of disease exposure, diminished antibody response in sub-groups like the elderly and the immunocompromised, and the emergence of newer mutant strains with grea…”
BackgroundJaafar, R., Boschi, C., Aherfi, S., Bancod, A., Bideau, M. L., Edouard, S., Colson, P., Chahinian, H., Raoult, D., Yahi, N., et al. (2021) · Viruses · doi:10.3390/v13112177 · Cited by 23
“The results from phase III clinical trials in the United Kingdom revealed that the BNT162b2 and AZD1222 vaccines were highly effective when using a two-shot protocol with a target interval of three and four weeks, respectively, between doses [36].”
BackgroundMatsui, Y., Li, L., Prahl, M. K., Cassidy, A. G., Özarslan, N., Golan, Y., Gonzalez, V. J., Lin, C. Y., Jigmeddagva, U., Chidboy, M. A., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.157354 · Cited by 23
“Because vaccine efficacy was generally consistent across subgroups stratified by age, race, and ethnicity in the general population (55, 56), it is unlikely that these factors would affect the biologic immune response to an mRNA vaccine and SARS-CoV-2 in pregnancy.”
Prefusion spike protein conformational changes are slower in SARS-CoV-2 than in SARS-CoV-1
Kumar, V. G., Ogden, D. S., Isu, U. H., Polasa, A., Losey, J., & Moradi, M. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101814 · Cited by 22
Zhugunissov, K. D., Zakarya, K. D., Khairullin, B. M., Orynbayev, M. B., Abduraimov, Y. O., Kassenov, M. M., Sultankulova, K. T., Kerimbayev, A. A., Nurabayev, S. S., Myrzakhmetova, B. S., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.720437 · Cited by 27
“5 years, but also successfully conducted three phases of clinical trials (Polack et al., 2020; Baden et al., 2021; Logunov et al., 2021; Voysey et al., 2021).”
BackgroundImpaired Humoral Immunity to SARS-CoV-2 Vaccination in Non-Hodgkin Lymphoma and CLL PatientsPreprint
Diefenbach, C., Caro, J., Koide, A., Grossbard, M. L., Goldberg, J. D., Raphael, B. G., Hymes, K. B., Moskovits, T., Kreditor, M., Kaminetzky, D., et al. (2021) · medRxiv · doi:10.1101/2021.06.02.21257804 · Cited by 26
“Although Phase 3 registration trials of all 3 FDA approved SARS-CoV-2 vaccines showed high efficacy in preventing symptomatic infection independent of age, none of them included patients with hematologic malignancies (7-9).”
BackgroundCan mRNA Vaccines Turn the Tables During the COVID-19 Pandemic? Current Status and Challenges
Anthony, D. P. S., Sivakumar, K., Venugopal, P., Sriram, D. K., & George, M. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01022-9 · Cited by 23
COVID-19 and HSCT (Hematopoietic stem cell transplant)
Strasfeld, L. M. (2022) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2022.101399 · Cited by 25
“and ultimate FDA approval specifically excluded HSCT recipients and other severely immunocompromised individuals (54-56).”
BackgroundKarbiener, M., Farcet, M. R., Zollner, A., Masuda, T., Mori, M., Moschen, A. R., & Kreil, T. R. (2022) · npj Vaccines · doi:10.1038/s41541-022-00455-3 · Cited by 20
Disanto, G., Galante, A., Cantù, M., Sacco, R., Mele, F., Eisler, J. J., Keller, F., Bernasconi, E., Sallusto, F., Zecca, C., et al. (2022) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200043 · Cited by 22
Relating In Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) Trial
Cromer, D., Reynaldi, A., Steain, M., Triccas, J. A., Davenport, M. P., & Khoury, D. S. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac075 · Cited by 23
“In the recent randomised control trials, the CVnCoV vaccine was administered in a 2 dose regimen with 4 weeks between doses [3], which is very similar to the BNT162b2 and mRNA1273 vaccine trials, where 2 dose regimens were also used with 3 and 4 week spacing, respectively [4, 5].”
BackgroundMethodAgent-based simulations for protecting nursing homes with prevention and vaccination strategies
Lasser, J., Zuber, J. A., Sorger, J., Dervić, E., Ledebur, K., Lindner, S. D., Klager, E., Kletečka-Pulker, M., Willschke, H., Stangl, K., et al. (2021) · Journal of The Royal Society Interface · doi:10.1098/rsif.2021.0608 · Cited by 24
Serwaa, D., Osei‐Boakye, F., Nkansah, C., Ahiatrogah, S., Lamptey, E., Abdulai, R., Antwi, M. H., Wirekoh, E. Y., Owusu, E., Buckman, T. A., et al. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1963600 · Cited by 24
“Data from other community-based surveys provide evidence to support our reports of higher frequency of side-effects in younger than in older individuals.(10,21) The possible explanation could be the increase in titer of post vaccine expression of counterbalance antibodies in younger people,(22) confirming the associat…”
BackgroundResultCOVID-19 Vaccine in the Kingdom of Saudi Arabia: A True Operation Warp Speed
Barry, M. A., & BaHammam, A. S. (2021) · Journal of Nature and Science of Medicine · doi:10.4103/jnsm.jnsm_8_21 · Cited by 29
mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant
Nanishi, E., McGrath, M. E., O’Meara, T. R., Barman, S., Yu, J., Wan, H., Dillen, C. A., Menon, M., Seo, H., Song, K., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03765-3 · Cited by 21
Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians
Wang, B., Goh, Y. S., Fong, S., Young, B. E., Ngoh, E. Z. X., Chavatte, J., Salleh, S. N. M., Yeo, N. K., Amrun, S. N., Hor, P. X., et al. (2021) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2021.100276 · Cited by 27
“In less than a year, BNT162b2, an mRNA-based accine developed by BioNTech-Pfizer [2] , became the first ever pproved COVID-19 vaccine in December 2020.”
Fuzo, C. A., Júnior, R. B. M., Fraga‐Silva, T. F. D. C., Amstalden, M. K., Léo, T. C. D., Souza, J. D. P., de Lima, T. M., Faccioli, L. H., Okamoto, D. N., Juliano, M. A., et al. (2022) · Drug Development Research · doi:10.1002/ddr.21982 · Cited by 22
Shields, L. B. E., Iyer, V. G., Zhang, Y. P., et al. (2022) · Case Reports in Neurology · doi:10.1159/000521462 · Cited by 23
The Coming of Age of Nucleic Acid Vaccines during COVID-19
Rando, H. M., Lordan, R., Kolla, L., Sell, E., Lee, A. J., Wellhausen, N., Naik, A. S., Kamil, J. P., Gitter, A., Greene, C. S., et al. (2023) · mSystems · doi:10.1128/msystems.00928-22 · Cited by 33
“In a phase II/III multinational trial, the Pfizer/BioNTech’s BNT162b2 vaccine was associated with a 95% efficacy against laboratory-confirmed COVID-19 and with mild-to-moderate local and systemic effects but a low risk of serious AEs when the prime-boost doses were administered 21 days apart (183).”
COVID-19 Vaccination for Endocrine Patients: A Position Statement from the Korean Endocrine Society
Ku, C. R., Jung, K. Y., Ahn, C. H., Moon, J. S., Lee, J. H., Kim, E. H., Kwon, H., Kim, H. K., Suh, S., Hong, S., et al. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.404 · Cited by 23
“The side effects of COVID-19 vaccines include pain at the injection site, fatigue, headache, myalgia, joint pain, chills, and fever [2,3].”
BackgroundMarchand, G. J., Masoud, A. T., & Medi, S. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2230828 · Cited by 23
RetractedThe future of COVID-19: A vaccine review
Vashi, A. P., & Coiado, O. C. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.08.011 · Cited by 25
“In developed ountries such as the United States, communities of color, in which he poor, the undereducated, and those without regular access to ealth services are overrepresented, are at a higher risk of infection 40].”
InfluentialClinical advancements in mRNA vaccines against viral infections
Fatima, M. T., Park, P., & Hong, K. (2024) · Clinical Immunology · doi:10.1016/j.clim.2024.110424 · Cited by 29
Darraj, M., & Al-Mekhlafi, H. (2022) · Vaccines · doi:10.3390/vaccines10020223 · Cited by 17
“A structured self-administered questionnaire of this survey was created after extensive review of the literature on adverse events of various COVID-19 vaccines [11,12,29].”
BackgroundMethodRaviv, Y., Betesh-Abay, B., Valdman‐Grinshpoun, Y., Cohen, L. B., Kassirer, M., & Sagy, I. (2022) · Case Reports in Rheumatology · doi:10.1155/2022/9698138 · Cited by 26
Microfluidics for Formulation and Scale-Up Production of Nanoparticles for Biopharma Industry
Yu, M., Mathew, A., Liu, D., Chen, Y., Wu, J., Zhang, Y., & Zhang, N. (2024) · AAPS introductions in the pharmaceutical sciences · doi:10.1007/978-3-031-60717-2_16 · Cited by 43
Chiem, K., Vasquez, D. M., Silvas, J. A., Park, J., Piepenbrink, M. S., Sourimant, J., Lin, M. J., Greninger, A. L., Plemper, R. K., Torrelles, J. B., et al. (2021) · Journal of Virology · doi:10.1128/jvi.01126-21 · Cited by 19
Samanovic, M. I., Oom, A. L., Cornelius, A. R., Gray-Gaillard, S. L., Karmacharya, T., Tuen, M., Wilson, J. P., Tasissa, M., Goins, S., Herati, R. S., et al. (2022) · Vaccines · doi:10.3390/vaccines10122152 · Cited by 23
Pani, A., Cento, V., Vismara, C., Campisi, D., Ruscio, F. D., Romandini, A., Senatore, M., Schenardi, P. A., Gagliardi, O. M., Giroldi, S., et al. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.08.013 · Cited by 22
Faustini, S. E., Shields, A. M., Banham, G. D., Wall, N. A., Al‐Taei, S., Tanner, C., Ahmed, Z., Efstathiou, E., Townsend, N., Goodall, M. D., et al. (2022) · Journal of Infection · doi:10.1016/j.jinf.2022.01.002 · Cited by 38
Panagiotopoulos, A. A., Tseliou, M., Karakasiliοtis, I., Kotzampasi, D. M., Daskalakis, V., Kesesidis, N., Notas, G., Lionis, C. D., Kampa, M., Pirintsos, S., et al. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.798 · Cited by 33
Human brain organoids to explore SARS‐CoV‐2‐induced effects on the central nervous system
Ostermann, P. N., & Schaal, H. (2023) · Reviews in Medical Virology · doi:10.1002/rmv.2430 · Cited by 24
Emmelot, M. E., Vos, M. W., Boer, M. C., Rots, N. Y., de Wit, J., van Els, C. A. C. M., & Kaaijk, P. (2022) · Viruses · doi:10.3390/v14071570 · Cited by 24
Capuano, R., Bisecco, A., Conte, M., et al. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.103724 · Cited by 23
Innate immune responses to three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine
Saresella, M., Piancone, F., Marventano, I., Hernis, A., Trabattoni, D., Invernizzi, M., Rosa, F. L., & Clerici, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.947320 · Cited by 29
“Notably, ILT-2 expressing NK cells were reduced even more robustly in COVID-19-recovereed vaccines.”
BackgroundInfluentialParsonage-Turner Syndrome After SARS-CoV-2 BNT162b2 Vaccine
Coffman, J. R., Randolph, A. C., & Somerson, J. S. (2021) · JBJS Case Connector · doi:10.2106/jbjs.cc.21.00370 · Cited by 23
Zhao, H. H., Souders, C., Carmel, M. E., & Anger, J. T. (2021) · Urology · doi:10.1016/j.urology.2021.04.002 · Cited by 24
“To our knowledge, this is the first study to investigate urologic symptoms after COVID-19 vaccination as these details were not reported from the Pfizer-BioNTech and Moderna trial results.(4,5) While the current literature suggests that there may be urologic manifestations of COVID-19 infections, our investigation of…”
Lakhlifi, C., Lejeune, F., Rouault, M., Khamassi, M., & Rohaut, B. (2023) · Cognitive Research Principles and Implications · doi:10.1186/s41235-023-00474-1 · Cited by 33
“…definitions and misconceptions (Colquhoun, 2017) and most recent literature (Baden et al., 2021; Haute Autorité de Santé, 2020; Olliaro, 2021; Polack et al., 2020), respectively Participants were instructed that several claims could be correct, and they had to give their answer (true/false)…”
BackgroundMethodImpact of Early SARS-CoV-2 Antiviral Therapy on Disease Progression
VITO, A. D., Colpani, A., Saderi, L., Puci, M. V., Zauli, B., Fiore, V., Fois, M., Meloni, M. C., Bitti, A., Castri, C. D., et al. (2022) · Viruses · doi:10.3390/v15010071 · Cited by 27
Beyond simple tails: poly(A) tail-mediated RNA epigenetic regulation
Liu, J., & Lu, F. (2024) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2024.06.013 · Cited by 26
Sullivan, D. J., Focosi, D., Hanley, D. F., Cruciani, M., Franchini, M., Ou, J., Casadevall, A., & Paneth, N. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29310 · Cited by 36
“3,4 While many small molecules were repurposed as antivirals during the early stages of the pandemic, oral antivirals developed against SARS ‐ CoV ‐ 2 for outpatients were not authorized and available until December 2021, when nirmatrelvir/ ritonavir 5 and molnupiravir 6 were approved.”
BackgroundReynolds, L., Dewey, C. E., Asfour, G., & Little, M. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1229716 · Cited by 26
Moeed, A., Najeeb, H., Saleem, A., Asghar, M. S., Rafi, H. M., Khattak, A. K., Bilal, Z., & Seboka, B. T. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.911518 · Cited by 25
Hunagund, S., Golan, Y., Asiodu, I. V., Prahl, M. K., & Gaw, S. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.910383 · Cited by 30
Palumbo, G. A., Cambria, D., Spina, E. L., Duminuco, A., Laneri, A., Longo, A., Vetro, C., Giallongo, S., Romano, A., Raimondo, F. D., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1117815 · Cited by 22
“On December 2020, results of the BNT162b2 mRNA Covid-19 vaccine clinical trial results were published (4), demonstrating that fully vaccinated people gained a 95% protection against Covid-19, usually reaching a titer >1000 AU/ml (5–7).”
BackgroundRecent Developments in SARS-CoV-2 Neutralizing Antibody Detection Methods
Ndzouboukou, J. B., Zhang, Y., & Fan, X. (2021) · Current Medical Science · doi:10.1007/s11596-021-2470-7 · Cited by 24
An Agent-based Decision Support for a Vaccination Campaign
Sulis, E., & Terna, P. (2021) · Journal of Medical Systems · doi:10.1007/s10916-021-01772-1 · Cited by 27
“1 3 the first and second dose the efficacy is 52%, and the protection concerns starts about twelve days after the first dose [33].”
BackgroundWang, C. Y., Rademaker, M., Tate, B. J., Baker, C., & Foley, P. A. (2021) · Australasian Journal of Dermatology · doi:10.1111/ajd.13593 · Cited by 23
Elkhalifa, D. H., Rayan, M., Negmeldin, A. T., Elhissi, A. M. A., & Khalil, A. A. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112385 · Cited by 24
The influence of interval between doses on response to vaccines
Rodrigues, C. M. C., & Plotkin, S. A. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.10.050 · Cited by 27
“The rationale for this decision was that high VE after one dose of both vaccines had been reported [2,3], therefore more people could be protected against severe disease by widespread use of a single dose of vaccination.”
Selective Reduction of Esters to Access Aldehydes Using Fiddler Crab-Type Boranes
Dudás, Á., Gyömöre, Á., Mészáros, B. B., Gondár, S., Adamik, R., Fegyverneki, D., Papp, D., Otte, K. B., Ayala, S., Daru, J., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c14596 · Cited by 23
“Evaluation of the phthalimide protecting groups confirmed a preference for the less Lewis basic protecting group in the catalytic process; phthalimide acetal 54 was accessed in only 44% yield, however, tetrachlorophthalimide acetal 55 was generated in 89% yield.”
Trends in COVID-19 Vaccine Administration and Effectiveness Through October 2021
Winkelman, T. N. A., Rai, N. K., Bodurtha, P. J., Chamberlain, A. M., DeSilva, M. B., Jeruzal, J. N., Johnson, S., Kharbanda, A. B., Klyn, N. A. M., Mink, P. J., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.5018 · Cited by 24
Luo, B., Yuan, Y., Zhu, Y., Liang, S., Dong, R., Hou, J. L., Li, P., Xing, Y., Lu, Z., Lo, R., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.988794 · Cited by 23
Self-citationUaprasert, N., Panrong, K., Rojnuckarin, P., & Chiasakul, T. (2021) · Thrombosis Journal · doi:10.1186/s12959-021-00340-4 · Cited by 25
“Polack, 2020 [3] mRNA Primary analysis of safety and efficacy from the phase 2/3 part of BNT162b2 in preventing symptomatic COVID-19 in persons ≥16 years Median follow-up: 2 months BNT162b2 (30 μg), 2 doses 21 days apart 18,860 (21621) 52 (Range; 16–89) 51.”
BackgroundGe, J., Digitale, J. C., Pletcher, M. J., & Lai, J. C. (2023) · Hepatology · doi:10.1002/hep.32780 · Cited by 23
ATOM-1: A Foundation Model for RNA Structure and Function Built on Chemical Mapping DataPreprint
Boyd, N. R., Anderson, B., Townshend, B., Chow, R., Stephens, C. J., Rangan, R., Kaplan, M., Corley, M., Tambe, A., Ido, Y., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.13.571579 · Cited by 27
“RNA-based medicines have recently demonstrated significant therapeutic potential through the successful development of mRNA vaccines, antisense oligonucleotides (ASOs), siRNAs, and RNA editing therapies [1–6].”
BackgroundCosma, S. D., Carosso, A. R., Corcione, S., Cusato, J., Borella, F., Antonucci, M., Marozio, L., Revelli, A., Preti, M., Ghisetti, V., et al. (2021) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2021.103285 · Cited by 22
RNA therapies for CNS diseases
Francesco, V. D., Chua, A. J. K., Huang, D., D’souza, A. A., Yang, A., Bleier, B. S., & Amiji, M. M. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115283 · Cited by 27
Chen, Y.-T. (2022) · Health Policy and Technology · doi:10.1016/j.hlpt.2022.100699 · Cited by 28
“For example, the Pfizer-BioNTech BNT162b2 mRNA vaccine has 95% efficacy against symptomatic infection of COVID-19 [61].”
BackgroundVeli, N., Martin, C., Woolf, K., Nazareth, J., Pan, D., Al‐Oraibi, A., Baggaley, R. F., Bryant, L., Nellums, L. B., Gray, L. J., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02588-7 · Cited by 24
“Globally, vaccine programmes have been effective at preventing symptomatic disease [2], resulting in a reduced rate of hospitalisations and deaths [3].”
BackgroundALMuhizi, F., Ton-Leclerc, S., Fein, M. N., et al. (2022) · Frontiers in Allergy · doi:10.3389/falgy.2022.825164 · Cited by 23
“The authors proposed two hypotheses to explain this: (1) either the majority of these initial reactions did not have a true allergic origin or (2) they were allergic reactions but involved a non-IgE-mediated mechanism (22).”
BackgroundMolecular dynamics studies reveal structural and functional features of the SARS‐CoV‐2 spike protein
Pipitò, L., Rujan, R., Reynolds, C. A., & Deganutti, G. (2022) · BioEssays · doi:10.1002/bies.202200060 · Cited by 22
Teimouri, H., Taheri, S., Saidabad, F. E., Nakazato, G., Maghsoud, Y., & Babaei, A. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117844 · Cited by 29
SARS-CoV-2 Vaccination and Neuroimmunological Disease: A Review
Willison, A., Pawlitzki, M., Lunn, M. P., Willison, H. J., Hartung, H., & Meuth, S. G. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2023.5208 · Cited by 26
From in vitro to in vivo: The Dominant role of PEG-Lipids in LNP performance
Borah, A., Giacobbo, V., Binici, B., Baillie, R., & Perrie, Y. (2025) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2025.114726 · Cited by 30
Debbag, R., Rudin, D., Ceddia, F., & Watkins, J. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-01079-x · Cited by 32
Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine
Gandolfo, C., Anichini, G., Mugnaini, M., Bocchia, M., Terrosi, C., Sicuranza, A., Savellini, G. G., Gozzetti, A., Franchi, F., & Cusi, M. G. (2022) · Vaccines · doi:10.3390/vaccines10020171 · Cited by 24
“It is of primary interest to know the real correlates of protection from COVID-19 vaccines therefore a deeper knowledge of the type of immunity and its duration after vaccination could help to understand whether and when it is necessary to initiate further jabs and improve the vaccine performance against variants.”
BackgroundInfluentialYendewa, G. A., Perez, J. A., Patil, N. T., & McComsey, G. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1297195 · Cited by 29
Self-citationEngineering a streamlined virus-like particle for programmable tissue-specific gene delivery
Han, J., Bai, H., Li, F., Zhang, Y., Zhou, Q., & Li, W. (2025) · Nature Communications · doi:10.1038/s41467-025-64181-9 · Cited by 29
Nussbaum, J. C., Cao, X., Railkar, R. A., Sachs, J. R., Spellman, D. S., Luk, J. A. M., Shaw, C. A., Cejas, P. J., Citron, M. P., Al-Ibrahim, M. S., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.05.062 · Cited by 24
Doubrovinskaia, S., Mooshage, C. M., Seliger, C., Lorenz, H., Nagel, S., Lehnert, P., Purrucker, J. C., Wildemann, B., Bendszus, M., Wick, W., et al. (2022) · European Journal of Neurology · doi:10.1111/ene.15602 · Cited by 24
The role of mild and asymptomatic infections on COVID-19 vaccines performance: A modeling study
Aguiar, M., Van-Dierdonck, J. B., Mar, J., & Stollenwerk, N. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.10.012 · Cited by 23
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.